Novartis Unit Sandoz Announced Mylight Study Met Its Primary Efficacy Endpoint And Showed No Clinically Meaningful Differences To Reference Aflibercept
Portfolio Pulse from Charles Gross
Novartis' unit Sandoz announced that its Mylight Phase III study for biosimilar aflibercept, a treatment for wet macular degeneration, met its primary efficacy endpoint. The study showed no clinically meaningful differences between the biosimilar aflibercept and the reference biologic, Eylea.
August 15, 2023 | 8:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' unit Sandoz's successful Mylight Phase III study for biosimilar aflibercept could potentially boost Novartis' market position in the treatment for wet macular degeneration.
The successful completion of the Mylight Phase III study for biosimilar aflibercept by Novartis' unit Sandoz indicates a positive development for the company. This could potentially lead to an increase in Novartis' market share in the treatment for wet macular degeneration, thereby positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100